Plan now to achieve a higher valuation tomorrow

Biotechnology businesses may know that selling their business to a pharmaceutical company is an attractive exit strategy, but how can you ensure the process runs smoothly?

In this Guide to Selling Your Biotechnology Business, we walk through how to prepare for each step of the sale, from what to address now to make your business attractive for a sale, to tips for negotiating final offers and letters of intent.

Read this guide to learn how to prepare for and execute a sale of a biotechnology business.

In this guide you will learn:

  • How to prepare your business for sale—including how to address areas like management, tax, and forecasted profitability to drive valuation
  • How to address areas of risk such as SOX compliance, supply chain and technical and regulatory considerations
  • How to determine if your business is prepared for a lengthy and challenging process
  • Considerations when structuring the sale
  • The right number of buyers to approach
  • Advice for handling meetings, offers, negotiations and letters of intent

Event

Month D, YYYY

City
Address

Download the Guide

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Explore Additional Related Insights From BDO Life Sciences


Card image cap

Biotech IPO Checklist: The Road to Going Public & Beyond

IPOs can be a thrilling milestone, but transforming into a public entity is not an easy undertaking. Biotech companies should consider the following steps—and answer the corresponding questions—ahead of IPO consideration.

Card image cap

Q1 2023 Biotech Brief: Biotech Makes a U-Turn

Are you thinking about a biotech transaction? If so, read BDO’s analysis of the NASDAQ Biotech Index (NBI) December 2022 reconstitution to understand what is shaping valuations, research areas and investment.

Card image cap

Summer 2022 Biotech Brief: After the Biotech Boom

BDO's analysis of the most recent 10-K SEC filings of companies listed on the NASDAQ Biotechnology Index (NBI) shows that the break-neck pace of 2020 is over, but the biotech industry remains resilient.

Card image cap

Special title treatment

With supporting text below as a natural lead-in to additional content.

Card image cap

Special title treatment

With supporting text below as a natural lead-in to additional content.

Card image cap

Special title treatment

With supporting text below as a natural lead-in to additional content.